Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Observational 1

Sponsor

Cancer Type

Thoracic 1Genitourinary 1Gastrointestinal 1

Conditions

Neoplasms 5Colorectal Neoplasms, Hereditary Nonpolyposis 3Colorectal Neoplasms 3Sarcoma 2Recurrence 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2Stage IIIb and IV Non Small Cell Lung Cancer 1Solid Tumor, Adult 1Rare Diseases 1Prostatic Neoplasms 1Ovarian Neoplasms 1Neuroblastoma 1Neoplastic Syndromes, Hereditary 1Neoplasm, Residual 1Neoplasm Metastasis 1Multiple Myeloma 1Mouth Neoplasms 1Microsatellite Instability 1Lymphoma, Non-Hodgkin 1Lung Neoplasms 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Hereditary Breast and Ovarian Cancer Syndrome 1Head and Neck Neoplasms 1Genetic Predisposition to Disease 1Colonic Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Medullary 1COVID-19 1Biliary Tract Neoplasms 1

Interventions

pembrolizumab 92Gemcitabine 56Nivolumab 50Cisplatin 39atezolizumab 37Carboplatin 30avelumab 29enfortumab vedotin 26Docetaxel 23Magnetic Resonance Spectroscopy 19Mitomycin 17Ipilimumab 17Paclitaxel 16Specimen Handling 14durvalumab 11toripalimab 10sacituzumab govitecan 10Pemetrexed 10cabozantinib 9Taxes 8vinflunine 7Cyclophosphamide 7tislelizumab 6Injections 6Bevacizumab 6pemigatinib 5fludarabine 5disitamab vedotin 5Standard of Care 5Radiosurgery 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Transitional Cell × High-Throughput Nucleotide Sequencing × Clear all
NCT03794128 2020-09-11

A Study of Personalized Neoantigen Cancer Vaccines

Gritstone bio, Inc.

Completed
93 enrolled
GastrointestinalGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡